A Telenti

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. pmc Genomics meets HIV-1
    Amalio Telenti
    Institute of Microbiology, University Hospital, University of Lausanne, 1011 Lausanne, Switzerland
    Nat Rev Microbiol 4:865-73. 2006
  2. doi request reprint Genomic approaches to the study of HIV‐1 acquisition
    Amalio Telenti
    Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    J Infect Dis 202:S382-6. 2010
  3. pmc Host genes important to HIV replication and evolution
    Amalio Telenti
    Institute of Microbiology, University Hospital and University of Lausanne, 1011 Lausanne, Switzerland
    Cold Spring Harb Perspect Med 2:a007203. 2012
  4. pmc The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription
    Yasuo Ariumi
    Department of Microbiology and Molecular Medicine, University of Geneva and Frontiers in Genetics National Center for Competence in Research, Switzerland
    Retrovirology 3:47. 2006
  5. pmc Patterns of evolution of host proteins involved in retroviral pathogenesis
    Millan Ortiz
    Institute of Microbiology, University of Lausanne, Switzerland
    Retrovirology 3:11. 2006
  6. pmc Role of common human TRIM5alpha variants in HIV-1 disease progression
    Valerie Goldschmidt
    Institute of Microbiology and University Hospital, University of Lausanne, Switzerland
    Retrovirology 3:54. 2006
  7. ncbi request reprint Pharmacogenetics of anti-HIV drugs
    A Telenti
    Institute of Microbiology, University of Lausanne, Lausanne, Switzerland
    Annu Rev Pharmacol Toxicol 48:227-56. 2008
  8. pmc Mapping of positive selection sites in the HIV-1 genome in the context of RNA and protein structural constraints
    Joke Snoeck
    Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    Retrovirology 8:87. 2011
  9. doi request reprint Safety concerns about CCR5 as an antiviral target
    Amalio Telenti
    Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Curr Opin HIV AIDS 4:131-5. 2009
  10. doi request reprint ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
    Rubin Lubomirov
    Institute of Microbiology, Service of Infectious Diseases, Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 20:217-30. 2010

Detail Information

Publications110 found, 100 shown here

  1. pmc Genomics meets HIV-1
    Amalio Telenti
    Institute of Microbiology, University Hospital, University of Lausanne, 1011 Lausanne, Switzerland
    Nat Rev Microbiol 4:865-73. 2006
    ..However, a key obstacle to progress remains the scarcity of appropriate human cohorts available for genomic research...
  2. doi request reprint Genomic approaches to the study of HIV‐1 acquisition
    Amalio Telenti
    Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    J Infect Dis 202:S382-6. 2010
    ..The pattern of enrichment for CCR5 Δ32 homozygosis should serve as the standard for assessing the extent to which a given cohort (of white subjects) includes a large proportion of exposed uninfected individuals...
  3. pmc Host genes important to HIV replication and evolution
    Amalio Telenti
    Institute of Microbiology, University Hospital and University of Lausanne, 1011 Lausanne, Switzerland
    Cold Spring Harb Perspect Med 2:a007203. 2012
    ..g., to include host whole exome and whole genome sequencing) and in breadth (in particular, by integrating multiple data types)...
  4. pmc The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription
    Yasuo Ariumi
    Department of Microbiology and Molecular Medicine, University of Geneva and Frontiers in Genetics National Center for Competence in Research, Switzerland
    Retrovirology 3:47. 2006
    ..These results suggest that the incoming PICs might recruit INI1 to facilitate proviral transcription...
  5. pmc Patterns of evolution of host proteins involved in retroviral pathogenesis
    Millan Ortiz
    Institute of Microbiology, University of Lausanne, Switzerland
    Retrovirology 3:11. 2006
    ....
  6. pmc Role of common human TRIM5alpha variants in HIV-1 disease progression
    Valerie Goldschmidt
    Institute of Microbiology and University Hospital, University of Lausanne, Switzerland
    Retrovirology 3:54. 2006
    ..However, the longterm effect of carrying Trim5alpha variants on disease progression in individuals infected with HIV-1 has not previously been investigated...
  7. ncbi request reprint Pharmacogenetics of anti-HIV drugs
    A Telenti
    Institute of Microbiology, University of Lausanne, Lausanne, Switzerland
    Annu Rev Pharmacol Toxicol 48:227-56. 2008
    ..It is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future...
  8. pmc Mapping of positive selection sites in the HIV-1 genome in the context of RNA and protein structural constraints
    Joke Snoeck
    Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    Retrovirology 8:87. 2011
    ....
  9. doi request reprint Safety concerns about CCR5 as an antiviral target
    Amalio Telenti
    Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Curr Opin HIV AIDS 4:131-5. 2009
    ..This review highlights gaps in our understanding of epidemiology of infections that are modulated by CCR5, in particular, in HIV-infected individuals...
  10. doi request reprint ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
    Rubin Lubomirov
    Institute of Microbiology, Service of Infectious Diseases, Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 20:217-30. 2010
    ....
  11. doi request reprint Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study
    B Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    HIV Med 12:279-88. 2011
    ..The long-term outcome of antiretroviral therapy (ART) is not assessed in controlled trials. We aimed to analyse trends in the population effectiveness of ART in the Swiss HIV Cohort Study over the last decade...
  12. pmc Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study
    Rubin Lubomirov
    Institute of Microbiology, University Hospital of Lausanne, 1011 Lausanne, Switzerland
    J Infect Dis 203:246-57. 2011
    ..Poor tolerance and adverse drug reactions are main reasons for discontinuation of antiretroviral therapy (ART). Identifying predictors of ART discontinuation is a priority in HIV care...
  13. doi request reprint Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals
    Margalida Rotger
    Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    Clin Infect Dis 51:1090-8. 2010
    ..Recent genome-wide association studies have reliably associated multiple single nucleotide polymorphisms (SNPs) to DM in the general population...
  14. doi request reprint Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Basel, Basel, Switzerland
    Clin Infect Dis 48:1459-66. 2009
    ..We investigated the incidence and outcome of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected individuals before and after the introduction of combination antiretroviral therapy (cART) in 1996...
  15. doi request reprint In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
    Julia Di Iulio
    Institute of Microbiology Division of Clinical Pharmacology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 19:300-9. 2009
    ..We hypothesize that genetic variability in this gene may contribute to the particularly high, unexplained variability in EFV exposure in individuals with limited CYP2B6 function...
  16. doi request reprint Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals
    M Arab-Alameddine
    Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Clin Pharmacol Ther 85:485-94. 2009
    ..Therefore, dosage adjustment in accordance with the type of polymorphism (CYP2B6, CYP2A6, or CYP3A4) is required in order to maintain EFV within the therapeutic target levels...
  17. doi request reprint Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study
    R Weber
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital, Zurich, Raemistrasse 100, Zurich CH 8091, Switzerland
    HIV Med 10:407-16. 2009
    ..Design A prospective observational study of all participants in the Swiss HIV Cohort Study followed between 1997 and 2006 was carried out...
  18. ncbi request reprint Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study
    K Boubaker
    University Hospital of Lausanne, 1011 Lausanne, Switzerland
    Clin Infect Dis 33:1931-7. 2001
    ..Age, sex, or stage of infection with human immunodeficiency virus were not predictive of hyperlactatemia. Determination of lactate levels may prove useful in the screening for mitochondrial toxicity...
  19. pmc Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals
    Margalida Rotger
    Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    PLoS Pathog 6:e1000781. 2010
    ..Overall, changes in global RNA expression reflect responses to viral replication rather than a mechanism that might explain viral control...
  20. pmc No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy
    Millan Ortiz
    Institute of Microbiology, University Hospital Center, and University of Lausanne, Switzerland
    J Infect Dis 203:620-4. 2011
    ..3 and 3.7 years, respectively). In HIV-infected persons, the development of lipoatrophy is unlikely to be associated with accumulation of mtDNA mutations detectable in peripheral blood...
  21. doi request reprint A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort
    Patrick Taffe
    Data Center, Swiss HIV Cohort Study, CHUV, Lausanne, Switzerland
    Stat Med 27:4835-53. 2008
    ..Results of simulation studies indicated that the imputation procedure worked well, despite the intrinsic high volatility of the CD4 marker...
  22. pmc Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1
    G Bleiber
    Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
    J Virol 75:3291-300. 2001
    ..These data underscore the complex relationship between PR and RT adaptive changes and viral evolution in antiretroviral drug-resistant HIV-1...
  23. ncbi request reprint New developments in laboratory monitoring of HIV-1 infection
    A Telenti
    Division of Infectious Diseases and Institute of Microbiology, Center Hospitalier UniversitaireVaudois, Lausanne, Switzerland
    Clin Microbiol Infect 8:137-43. 2002
    ..These approaches may in the future provide highly individualized disease management...
  24. doi request reprint Coping with an HIV infection. A multicenter qualitative survey on HIV positive adolescents' perceptions of their disease, therapeutic adherence and treatment
    Pierre Andre Michaud
    Research Group on Adolescent Health, Institute for Social and Preventive Medicine, University of Lausanne, Switzerland
    Swiss Med Wkly 140:247-53. 2010
    ....
  25. pmc Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance
    Julia Di Iulio
    Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Hepatology 53:1446-54. 2011
    ....
  26. ncbi request reprint Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy
    Mireia Arnedo
    Institute of Microbiology, University of Lausanne, Switzerland
    Pharmacogenet Genomics 17:755-64. 2007
    ..Single nucleotide polymorphisms in multiple genes involved in lipid transport and metabolism are presumed to modulate the risk of dyslipidemia in response to antiretroviral therapy...
  27. ncbi request reprint Limits to potent antiretroviral therapy
    A Telenti
    Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Rev Med Virol 10:385-93. 2000
    ..Treatment strategies need to take into account these limits to better target those HIV-infected patients who could benefit the most from antiretroviral therapy...
  28. pmc In vitro whole-genome analysis identifies a susceptibility locus for HIV-1
    Corinne Loeuillet
    Institute of Microbiology, University Hospital, University of Lausanne, Lausanne, Switzerland
    PLoS Biol 6:e32. 2008
    ..Genetic analysis of in vitro cellular phenotypes provides an attractive approach for the discovery of susceptibility loci to infectious agents...
  29. ncbi request reprint The genetic cohorts: facing the new challenges in infectious diseases. The HIV model
    Amalio Telenti
    Institute of Microbiology, University Hospital, Lausanne, Switzerland
    Enferm Infecc Microbiol Clin 22:337-41. 2004
    ..This review highlights ethical and practical issues on developing genetic cohorts by using the model of the Swiss HIV Cohort Study...
  30. pmc Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein
    S Peters
    Division of Infectious Diseases, University Hospital, Lausanne, Switzerland
    J Virol 75:9644-53. 2001
    ....
  31. doi request reprint The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir
    Sara Colombo
    Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    J Infect Dis 198:864-7. 2008
    ..2%, respectively; P < .0001). Therefore, HCP5 genotyping could serve as a simple screening tool for ABC-HSR, particularly in settings where sequence-based HLA typing is not available...
  32. pmc Typing of Pneumocystis carinii f. sp. hominis by single-strand conformation polymorphism of four genomic regions
    P M Hauser
    Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Clin Microbiol 35:3086-91. 1997
    ..Multitarget typing of P. carinii hominis by PCR-SSCP should allow investigation of strain diversity and thus be useful for future epidemiological studies...
  33. ncbi request reprint Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
    J Fellay
    University Hospital of Lausanne, Lausanne, Switzerland
    Lancet 358:1322-7. 2001
    ..Such data provides a reference for regimen-specific and compound-specific adverse events and could be useful in postmarketing analyses of toxic effects...
  34. ncbi request reprint [A primer on the management of antiviral resistance in chronic hepatitis B]
    C Doerig
    Service de Gastroentérologie et d Hépatologie, CHUV, 1011 Lausanne
    Rev Med Suisse 5:203-4, 206-8,. 2009
    ..The purpose of this concise review is to provide an introduction to the prevention, diagnosis and management of antiviral resistance in chronic hepatitis B...
  35. pmc Antiretroviral activity of ancestral TRIM5alpha
    Valerie Goldschmidt
    Institute of Microbiology, CHUV 1011 Lausanne, Switzerland
    J Virol 82:2089-96. 2008
    ..Our study sheds new light on the evolution of the intrinsic antiviral defense machinery and illustrates the utility of functional evolutionary reconstruction for characterizing recently emerged protein differences...
  36. doi request reprint HIV-1 elite controllers: beware of super-infections
    Olivier Clerc
    Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne 1011, Switzerland
    J Clin Virol 47:376-8. 2010
    ..This report indicates that elite controllers should be informed of the risk of super-infection, and illustrates the complexity of mounting broad anti-HIV immunity...
  37. ncbi request reprint Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression
    Christophe Butticaz
    Infectious Diseases and Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, CHUV, Lausanne, Switzerland
    Antivir Ther 8:373-7. 2003
    ..Protection was maintained at very high multiplicity of infection. This and other recent reports on RNAi should open a debate about the use of RNAi gene therapy for HIV infection...
  38. pmc Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression
    Gabriela Bleiber
    Institute of Microbiology, University of Lausanne, Switzerland
    J Virol 79:12674-80. 2005
    ..8 years the period from 500 CD4 T cells/mul to <200 CD4 T cells/mul...
  39. ncbi request reprint Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
    Philip E Tarr
    Infectious Diseases Service, University Hospital, Lausanne, Switzerland
    J Infect Dis 191:1419-26. 2005
    ..Single-nucleotide polymorphisms in genes involved in lipoprotein and adipocyte metabolism may explain why dyslipidemia and lipoatrophy occur in some but not all antiretroviral therapy (ART)-treated individuals...
  40. ncbi request reprint MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment
    Gabriela Bleiber
    Institute of Microbiology and Division of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland
    J Infect Dis 189:583-6. 2004
    ....
  41. doi request reprint CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
    Clin Infect Dis 47:1093-101. 2008
    ....
  42. doi request reprint Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study
    Helen Kovari
    Divisions of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich CH 8091, Switzerland
    Clin Infect Dis 49:626-35. 2009
    ..Postulated pathogenesis includes prolonged exposure to antiretroviral therapy, particularly didanosine...
  43. ncbi request reprint Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy
    M Depairon
    Division of Hypertension and Vascular Medicine, CHUV University Hospital, Lausanne, Switzerland
    AIDS 15:329-34. 2001
    ....
  44. doi request reprint Evolutionary trajectories of primate genes involved in HIV pathogenesis
    Millan Ortiz
    Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    Mol Biol Evol 26:2865-75. 2009
    ..The systematic assessment of long-acting selective pressures on primate genomes is a useful tool to extend our understanding of genetic variation influencing contemporary susceptibility to HIV-1...
  45. ncbi request reprint Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
    Margalida Rotger
    Institute of Microbiology and Section of Infectious Diseases, University Hospital, Lausanne, Switzerland
    Pharmacogenet Genomics 15:1-5. 2005
    ..Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6). Allele 516 G>T (Gln172His) is associated with diminished activity of this isoenzyme, and may lead to differences in drug exposure...
  46. ncbi request reprint Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
    Jacques Fellay
    Division of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland
    Lancet 359:30-6. 2002
    ..This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes...
  47. doi request reprint Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection
    Anna Haas
    Institute of Microbiology, ETH Zurich, Zurich, Switzerland
    Gut 60:1506-19. 2011
    ..The mechanisms underlying B cell hyperactivation and the specificities of the resulting hypergammaglobulinaemia are only poorly understood...
  48. ncbi request reprint HIV epidemiology and treatment - 1999
    A Telenti
    Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Ocul Immunol Inflamm 7:129-32. 1999
    ..This paper reviews (1) current recommendations for the initiation of antiretroviral therapy, (2) the natural history of HIV infection after initiation of treatment, and (3) toxicity and resistance issues...
  49. ncbi request reprint A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART
    Catherine Fagard
    Divisions of Infectious Diseases, University Hospital, Geneva, Geneva, Switzerland
    AIDS 17:1487-92. 2003
    ..To explore the effect of granulocyte macrophage colony stimulating factor (GM-CSF) on viral load and CD4 cell count during interruption of highly active antiretroviral therapy (HAART)...
  50. ncbi request reprint Does tenofovir influence efavirenz pharmacokinetics?
    Margalida Rotger
    Institute of Microbiology, University Hospital, Lausanne, Switzerland
    Antivir Ther 12:115-8. 2007
    ..We evaluated the possibility of a pharmacokinetic interaction between TFV and EFV by assessing cross-sectional and longitudinal data in 169 individuals receiving EFV...
  51. doi request reprint Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study
    Margalida Rotger
    Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland
    Circ Cardiovasc Genet 2:621-8. 2009
    ..Recent genome-wide association studies have reliably associated common SNPs to dyslipidemia in the general population...
  52. ncbi request reprint Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Institute of Microbiology, Lausanne, Switzerland
    Clin Pharmacol Ther 80:307-18. 2006
    ..Efavirenz, mainly bound to albumin, was included as a control drug...
  53. pmc Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation
    Christophe Butticaz
    Institute of Microbiology, University Hospital of Lausanne, Lausanne, Switzerland
    J Virol 81:1502-5. 2007
    ....
  54. ncbi request reprint Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications
    Philip E Tarr
    Infectious Disease Service, University Hospital, Lausanne, Switzerland
    Antivir Ther 12:999-1013. 2007
    ..Comprehensive, whole genome approaches are increasingly being used...
  55. pmc Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection
    Angela Ciuffi
    Institute of Microbiology, University of Lausanne, Switzerland
    J Virol 78:10747-54. 2004
    ..The phenotype of provirus transcription was stable over time, indicating that it represents a genetic trait...
  56. ncbi request reprint Adaptation, co-evolution, and human susceptibility to HIV-1 infection
    Amalio Telenti
    Institute of Microbiology, CHUV, University of Lausanne, Switzerland
    Infect Genet Evol 5:327-34. 2005
    ..Thus, despite a recent entry of HIV-1 in humans, this pathogen might be already exerting evolutionary pressure on humans, by selecting a repertoire of restriction genes and susceptibility loci...
  57. ncbi request reprint Individualising HIV treatment--pharmacogenetics and immunogenetics
    Amalio Telenti
    Division of Infectious Diseases, University Hospital, CHUV 1011 Lausanne, Switzerland
    Lancet 359:722-3. 2002
  58. ncbi request reprint CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
    Gilbert R Kaufmann
    Basel Center for HIV Research, Division of Infectious Diseases, University Hospital, Basel, Switzerland
    Arch Intern Med 163:2187-95. 2003
    ..Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-term T-lymphocyte responses to HAART...
  59. ncbi request reprint Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration
    David Dalmau
    Institute of Microbiology, University Hospital, Lausanne, Switzerland
    Antivir Ther 10:867-72. 2005
    ....
  60. ncbi request reprint Spare post-exposure prophylaxis with round-the-clock HIV testing of the source patient
    G Greub
    Division of Infectious Diseases, University Hospital, Lausanne, Switzerland
    AIDS 15:2451-2. 2001
    ..7% during the second period. The adjusted relative odds ratio of PEP during the second compared with the first period, was 0.23. The availability of immediate HIV testing limits unnecessary occupational PEP...
  61. ncbi request reprint Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
    M Rotger
    Institute of Microbiology, University of Lausanne, Lausanne, Switzerland
    Clin Pharmacol Ther 81:557-66. 2007
    ..CYP2B6 poor metabolizer genotypes explain to a large extent EFV pharmacokinetics and identify individuals at risk of extremely elevated EFV plasma levels...
  62. ncbi request reprint Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Clin Pharmacol Ther 73:20-30. 2003
    ....
  63. ncbi request reprint Promoter polymorphisms and allelic imbalance in ABCB1 expression
    Corinne Loeuillet
    Institute of Microbiology, University Hospital, Lausanne, Switzerland
    Pharmacogenet Genomics 17:951-9. 2007
    ..The results of association studies have, however, been variable and it is not currently clear whether this polymorphism is functional or is in linkage disequilibrium with functionally distinct alleles...
  64. ncbi request reprint Spare non-occupational HIV post-exposure prophylaxis by active contacting and testing of the source person
    Gilbert Greub
    Division of Infectious Diseases, University Hospital, Lausanne, Switzerland
    AIDS 16:1171-6. 2002
    ..To reduce unnecessary use of PEP, we implemented a policy including active contacting of source persons and the availability of free, anonymous HIV testing ('PEP policy')...
  65. doi request reprint Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction
    Aurélie Fayet
    Division of Clinical Pharmacology, Centre Hospitalier Universataire Vaudois, Lausanne, Switzerland
    Ther Drug Monit 30:511-22. 2008
    ....
  66. ncbi request reprint Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study
    Enos Bernasconi
    Hospital of Lugano, Lausanne, Switzerland
    J Acquir Immune Defic Syndr 31:50-5. 2002
    ..1 [95% CI, 0.6-1.8]; 6-24 months, OR = 2.4 [95% CI, 1.7-3.5]; and >24 months, OR = 3.2 [95% CI, 2.4-4.3]). This study confirms the association between the use of stavudine and lipodystrophy...
  67. ncbi request reprint The central region of human immunodeficiency virus type 1 p6 protein (Gag residues S14-I31) is dispensable for the virus in vitro
    Gabriela Bleiber
    Division of Infectious Diseases, University of Lausanne, Lausanne, Switzerland
    J Gen Virol 85:921-7. 2004
    ..Extensive Pol deletion (deltaR20-D39, 42 % of p6(Pol)) did not alter protease autocleavage...
  68. ncbi request reprint Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo
    Sara Colombo
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Pharmacogenet Genomics 15:599-608. 2005
    ..Genetic polymorphism in these genes may be associated with changes in transport function...
  69. ncbi request reprint Transplacental passage of protease inhibitors at delivery
    Catia Marzolini
    Division of Clinical Pharmacology, University Hospital of Lausanne, Lausanne, Switzerland
    AIDS 16:889-93. 2002
    ..The aim of this study was to assess the extent of transplacental passage of PI at delivery...
  70. ncbi request reprint Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection
    Alexandre Harari
    Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland
    Blood 100:1381-7. 2002
    ..These results advance the characterization of antiviral memory CD4 T-cell response and the delineation of the potential mechanisms that likely prevent the generation of a robust CD4 T-cell immune response during primary infection...
  71. ncbi request reprint Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy
    Gilbert Greub
    University Hospital, Lausanne, Switzerland
    AIDS 16:1967-9. 2002
  72. ncbi request reprint ADME pathway approach for pharmacogenetic studies of anti-HIV therapy
    Rubin Lubomirov
    Institute of Microbiology, University Hospital and University of Lausanne, Bugnon 48, 1011 Lausanne, Switzerland
    Pharmacogenomics 8:623-33. 2007
    ..This review compiles information for future analysis of the role of specific genes/variants in the exposure and response to antiretroviral therapy to generate a ranked list of new genetic variants for future studies...
  73. ncbi request reprint The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study
    Christian Felley
    Division of Gastroenterology, and Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    AIDS 18:1521-7. 2004
    ..This study will evaluate the frequency of CFTR mutations and SPINK-1 polymorphisms in HIV-positive patients with clinical pancreatitis or asymptomatic elevation of serum pancreatic enzymes...
  74. pmc Unique spectrum of activity of prosimian TRIM5alpha against exogenous and endogenous retroviruses
    Nadia Rahm
    Institute of Microbiology, University Hospital Center and University of Lausanne, CHUV 1011 Lausanne, Switzerland
    J Virol 85:4173-83. 2011
    ..Data on lemur TRIM5α and the prediction of ancestral simian sequences hint at an evolutionary scenario where antiretroviral specificity is prominently defined by the lineage-specific expansion of the variable loops of B30.2/SPRY...
  75. pmc Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure
    Amalio Telenti
    Division of Infectious Diseases and Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Virol 76:7868-73. 2002
    ..In contrast, viruses with stem-loop structures associated with 16 to 42% reductions in frameshift efficiency displayed no significant viral replication deficit...
  76. ncbi request reprint Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia
    Margalida Rotger
    Institute of Microbiology and Service of Infectious Diseases, University of Lausanne, Lausanne, Switzerland
    J Infect Dis 192:1381-6. 2005
    ..An understanding of the interaction between genetic predisposition and ART may help to identify individuals at highest risk for developing jaundice...
  77. ncbi request reprint Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7
    Margalida Rotger
    Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne Switzerland
    Pharmacogenet Genomics 17:885-90. 2007
    ..To evaluate the possibility of copy number variation (CNV) of CYP2B6...
  78. ncbi request reprint Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents
    Margalida Rotger
    Institute of Microbiology and University Hospital, Lausanne, Switzerland
    Curr HIV/AIDS Rep 3:118-25. 2006
    ..Despite the negative perception of genetic research among the general public, this type of investigation is now widely accepted by concerned parties: patients, relatives, and study volunteers...
  79. pmc Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital, CHUV, Lausanne 1011, Switzerland
    Antimicrob Agents Chemother 50:3801-8. 2006
    ..This population pharmacokinetic model, together with therapeutic drug monitoring and Bayesian dosage adaptation, can be helpful in the selection and adaptation of ATV doses...
  80. pmc Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, CHUV, Beaumont 633, Lausanne 1011, Switzerland
    Antimicrob Agents Chemother 48:3226-32. 2004
    ..The high interpatient pharmacokinetic variability represents an argument for therapeutic drug monitoring...
  81. ncbi request reprint Interactions of processed Nef (58-206) with virion proteins of HIV type 1
    Angela Ciuffi
    Institut de Microbiologie, Universite de Lausanne, Lausanne, Switzerland
    AIDS Res Hum Retroviruses 20:399-407. 2004
    ..In addition, this interaction suggests that Nef may accompany the reverse transcription and the preintegration complexes during the early steps of the infection cycle and potentially affect infectivity during these steps...
  82. ncbi request reprint Polymorphisms, resistance and drug response: beyond subtype-B HIV-1
    Amalio Telenti
    Antivir Ther 9:1. 2004
  83. pmc APOBEC3G genetic variants and their influence on the progression to AIDS
    Ping An
    Basic Research Program, SAIC Frederick, National Cancer Institute Frederick Cancer Research and Development Center, Frederick, MD 21702, USA
    J Virol 78:11070-6. 2004
    ..These studies suggest that there may be a modifying role of variants of APOBEC3G on HIV-1 disease progression that warrants further investigation...
  84. ncbi request reprint Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital of Bern, Switzerland
    Ther Drug Monit 28:332-8. 2006
    ..For drugs such as EFV or NVP, there may be room for therapeutic drug monitoring improvement using either direct CC determination or other predictive factors such as genotyping of transporters or metabolizing enzyme genes...
  85. ncbi request reprint Stable virulence levels in the HIV epidemic of Switzerland over two decades
    Viktor Müller
    Bioinformatics Group, Department of Plant Taxonomy and Ecology, Eotvos Lorand University, Budapest, Hungary
    AIDS 20:889-94. 2006
    ..To determine whether the virulence of HIV-1 has been changing since its introduction into Switzerland...
  86. ncbi request reprint Infrequent transmission of HIV-1 drug-resistant variants
    Sabine Yerly
    Laboratory of Virology and AIDS Center, Geneva University Hospital, Geneva, Switzerland
    Antivir Ther 9:375-84. 2004
    ..These data suggest that drug-resistant variants and in particular multidrug-resistant variants have a substantially reduced transmission capacity...
  87. ncbi request reprint Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort
    Bernard Hirschel
    Division of Infectious Diseases, Geneva University Hospital, CH 1211 Geneva 14, Switzerland
    AIDS 16:381-5. 2002
    ..Switchers were matched to non-switchers on the basis of calendar time, CD4 cell count, and viral load...
  88. ncbi request reprint Susceptibility to HIV infection--disentangling host genetics and host behavior
    Amalio Telenti
    J Infect Dis 193:4-6. 2006
  89. ncbi request reprint Update of the drug resistance mutations in HIV-1: Fall 2005
    Victoria A Johnson
    Veterans Affairs Medical Center, Birmingham, AL, USA
    Top HIV Med 13:125-31. 2005
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility...
  90. ncbi request reprint Update of the Drug Resistance Mutations in HIV-1: 2005
    Victoria A Johnson
    Veterans Affairs Medial Center, Birmingham, AL, USA
    Top HIV Med 13:51-7. 2005
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that, in isolation, may not reflect prior drug selective pressure or reduced drug susceptibility...
  91. ncbi request reprint Update of the drug resistance mutations in HIV-1: 2004
    Victoria A Johnson
    Veterans Affairs Medical Center, Birmingham, AL, USA
    Top HIV Med 12:119-24. 2004
  92. ncbi request reprint Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection
    Pierre Yves Bochud
    Institute for Systems Biology, Seattle, Washington State, USA
    AIDS 21:441-6. 2007
    ..Toll-like receptors (TLRs) have a key role in innate immunity and mutations in the genes encoding these receptors have been associated with increased or decreased susceptibility to infections...
  93. doi request reprint HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy
    Andri Rauch
    Division of Infectious Diseases, University Hospital Bern and University of Bern, Switzerland
    Clin Infect Dis 46:1921-5. 2008
    ..01, compared with HLA-Bw4 homozygotes). HLA-Bw4 homozygosity appears to predict an impaired CD4 T cell recovery after initiation of combination antiretroviral therapy...
  94. pmc Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study
    Jim Young
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Hebelstrasse 10, Basle, CH 4031, Switzerland
    BMJ 328:15. 2004
    ..To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART)...
  95. ncbi request reprint Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Switzerland
    Antivir Ther 12:1157-64. 2007
    ..Antiretroviral therapy (ART) decreases morbidity and mortality in HIV-infected patients but is associated with considerable adverse events (AEs)...
  96. pmc WGAViewer: software for genomic annotation of whole genome association studies
    Dongliang Ge
    Center for Population Genomics and Pharmacogenetics, Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Genome Res 18:640-3. 2008
    ....
  97. pmc Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8091 Zurich, Switzerland
    J Virol 77:13146-55. 2003
    ....
  98. ncbi request reprint Identifying safety concerns from genetic data: lessons from the development of CCR5 inhibitors
    Amalio Telenti
    Antivir Ther 12:147-8. 2007
  99. ncbi request reprint Drug resistance mutations in HIV-1
    Victoria A Johnson
    Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA
    Top HIV Med 11:215-21. 2003
    ..Drugs that have been approved by the US Food and Drug Administration (FDA) or available through expanded access protocols are included...
  100. ncbi request reprint Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types
    Viktor von Wyl
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistr 100, CH 8091 Zurich, Switzerland
    Arch Intern Med 167:1782-90. 2007
    ..Differences between these regimen types in the extent of the emergence of drug resistance on virological failure and the implications for further treatment options have rarely been assessed...
  101. ncbi request reprint Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population
    Christian Jaggy
    Swiss Re, Zurich, Switzerland
    Lancet 362:877-8. 2003
    ..Patients with successfully treated cancer have much the same excess death rates but are not excluded from life insurance policies...